OVERVIEW

Heart Failure: Evolving Treatment Choices and New Guidance is organized by Rockpointe Corporation.

Release Date: Oct 24, 2022
Expiration Date: Oct 24, 2023

Description:
The number of Americans with HF is increasing. Despite the many agents approved to manage HF, the prognosis has only improved somewhat, with a 5-year mortality rate after initial hospitalization of 42.3%. Guidelines are frequently updated, with the most recent ACC consensus on optimizing treatment published in 2022. Some agents to treat HFrEF are relatively new and several agents are in late-stage development. For patients with HFpEF, there are currently no approved therapies although there are agents in phase 3 clinical trials.

Heart Failure: Evolving Treatment Choices and New Guidance will address the rapidly shifting HF management paradigm, providing information about the most recent evidence-based recommendations for managing HFrEF, newer approved agents, and those agents for which approval is anticipated soon, as well as agents in the late-stage investigation for the management of HFpEF.

Educational Objectives:
At the conclusion of this education, participants should be able to:
• Evaluate the evidence showing the efficacy and safety of newer agents approved for the management of HFrEF
• Describe the mechanism of action of and efficacy and safety data for agents in late-stage development for the management of heart failure
• Develop individualized evidence-based management plans for patients with heart failure that are based on recommendations from the 2021 update to the ACC heart failure decision pathway